SAN DIEGO, Dec. 8, 2016 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient ...
News
- Avelas Presents Phase 1b Clinical Trial Data for AVB-620 at 2016 San Antonio Breast Cancer ...
- NY Gov. Cuomo to announce economic development awards
Cuomo's administration has used state investments in an attempt to spur growth in high-tech manufacturing, biotechnology, renewable energy, ...
- Cytocentrics Becomes CytoBioscience; New Name Reflects Expanded Company Footprint in ...
SAN ANTONIO--(BUSINESS WIRE)--Cytocentrics, Inc. has a new name ... “We are expanding our footprint in the biosciences arena,” Garvin said, “and ...
- Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in ...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, ... at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is ...
- San Antonio Company Cytocentrics Renames Itself CytoBioscience
The name change is happening in part because the San Antonio company is expanding its footprint in bioscience, CEO James Garvin said in a press ...